About Proximagen
Proximagen is a company based in London (United Kingdom) founded in 2004 by Peter Jenner was acquired by Upsher-Smith in June 2012. Proximagen has raised $96.5 million across 2 funding rounds from investors including Lundbeck and Upsher-Smith. Proximagen has completed 1 acquisition, including Minster Pharmaceuticals. Proximagen operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
- Headquarter London, United Kingdom
- Founders Peter Jenner
- SectorsHealthcare
- Website proximagen.com
- Social LinkedIn X Facebook
- Acquired by Upsher-Smith (Jun 2012)
- Legal Name Proximagen Group Limited
- Annual Revenue$164 (USD)-71as on Dec 31, 2016
- Net Profit$28.47 (USD)-60as on Dec 31, 2016
- Total Equity Funding$96.5M (USD)
in 2 rounds
- Latest Funding Round$16M (USD), Private Equity Round
Sep 2011
- InvestorsLundbeck
& 1 more
- Investments & Acquisitions
- Acquired byUpsher-Smith
(Jun 2012)
Funding Insights of Proximagen
Proximagen has successfully raised a total of $96.5M across 2 strategic funding rounds. The most recent funding activity was a Private Equity Round of $16 million completed in September 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $96.5M
- Total Rounds 2
- Last Round Private Equity Round — $16M
- First Round $80.5M
(Jun 2009)
- Investors Count 1
All 2 funding rounds of Proximagen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2011 | $16M | Private Equity Round | – | – | |
| Jun 2009 | $80.5M | Private Equity Round | – | – | – |
2 investors in total: 2 institutional.
Investors in Proximagen
Proximagen has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Lundbeck and Upsher-Smith.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Drugs for CNS disorders are developed and advanced. | 1915 | lundbeck.com | Copenhagen, Denmark | |
Manufacturer of generic drugs | 1919 | upsher-smith.com | Maple Grove, United States |
Investor details for Proximagen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Proximagen
2 people are tracked at Proximagen (2 in leadership).
| Name | Role | Group |
|---|---|---|
Peter Jenner | Founder | Leadership |
Kenneth Mulvany | CEO | Leadership |
Complete people profiles for Proximagen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Proximagen
Proximagen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Minster Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutics for CNS disorders including migraine were developed. | minsterpharma.com | London, United Kingdom | 2001 | Jan 2010 | $6.95M |
Complete acquisition details for Proximagen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Proximagen
5 dated milestones of Proximagen across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Proximagen is founded.
- Funding First funding round of $80.5M.
- Acquisition Acquires Minster Pharmaceuticals.
- Funding Latest funding round, Private Equity Round, of $16.0M.
- Exit Acquired by Upsher-Smith.
Competitors of Proximagen
Proximagen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| entradatx.com | 2016 | Boston, United States | $175.25M | 122 | Biologics platform developed for intracellular delivery in rare diseases. | |
| adamaspharma.com | 2002 | Emeryville, United States | $68.03M | 142 | Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics. | |
| sonomabio.com | 2012 | San Francisco, United States | $335M | 74 | T-cell-based therapies for autoimmune and degenerative diseases are developed. | |
| intracellulartherapies.com | 2002 | New York, United States | $80.87M | 600 | Developer of therapeutics for psychiatric and neurologic diseases | |
| juvlabs.com | 2017 | Dublin, Ireland | $289.89M | – | Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health | |
| alector.com | 2013 | San Francisco, United States | $214.78M | 211 | Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | |
| bluerocktx.com | 2016 | Boston, United States | $225M | 138 | Stem cell therapies are developed for cardiovascular and neurological diseases. |
Detailed competitors of Proximagen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Proximagen
10 companies that operate in the same segment as Proximagen (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Proximagen
Proximagen was founded in 2004 and raised its 1st funding round 5 years after it was founded.
Proximagen is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Kenneth Mulvany is the current CEO of Proximagen.
Proximagen is a funded company, having raised a total of $96.5M across 2 funding rounds to date. The company's 1st funding round was a Private Equity Round of $80.5M, raised on Jun 2009.
Annual revenue of Proximagen is $164 as on Dec 31, 2016.
Proximagen was founded in 2004 in London, United Kingdom, as a neuroscience research company. Drug development efforts are centered on neurodegenerative disorders such as Parkinsons disease and Alzheimers disease. Compounds are designed to target acetylcholine and dopamine receptors. Operations include research and preclinical activities in the biotechnology sector. The company was acquired by Upsher-Smith Laboratories in 2012.
Proximagen's top competitors include Alector, Intra-Cellular Therapies and Entrada Therapeutics.
Proximagen has made 1 acquisition, including Minster Pharmaceuticals.
Proximagen has 2 investors. Key investors include Lundbeck, and Upsher-Smith.
Proximagen operates through Proximagen Group Limited.
Yes. Proximagen was acquired by Upsher-Smith in June 2012.